ATS Labs, a portfolio company of Ampersand Capital Partners, has acquired the assets of MicroTest Labs, a provider of testing services for the medical devices.
MicroTest Labs (MTL) is a provider of testing services for the medical device, pharmaceutical and biotechnology industries. The services provided by MTL enhance product safety and security, speed time to market, and minimize supply chain disruption. The company was founded in 1984 and is based in Agawam, MA (www.MicroTestLabs.com).
ATS Labs is a provider of antimicrobial and biocide testing services, Customers include developers, manufacturers, and users of antimicrobial products. The company is based near Minneapolis in Eagan, MN (www.ATS-Labs.com).
The acquisition of MTL is the first step in the strategy of ATS to expand its microbiology and chemistry laboratory services platform to support the medical device and biopharmaceutical industries. The combined companies will soon be known as Accuratus Lab Services. It is expected that administrative functions will be consolidated, but the company will continue to operate at its locations in Eagan, MN and Agawam, MA.
“The acquisition of MicroTest by ATS has been a long time in the making and I could not be more pleased about the future of the two companies and how they will combine to create the market leader in providing microbiology and analytical chemistry testing services,” said Dr. Steve Richter, CEO of MicroTest Labs.
Ampersand Capital Partners makes middle market growth equity investments in the healthcare sector. Over the past twenty years, Ampersand has raised seven funds and invested in more than forty private healthcare companies. These activities have produced a 24% net pooled internal rate of return to the firm’s limited partners. Ampersand is based in Wellesley, MA (www.ampersandcapital.com).
“Like ATS, MicroTest has a strong reputation in the industries it serves, which is supported by long-standing client relationships. Leveraging the strengths of the two companies will only further enhance our ability to continuously exceed our client’s expectations,” said Dr. Tom Burnell, Executive Chairman of ATS.
2014 PEPD • Private Equity’s Leading News Magazine • 7-14-14